From football fields to military training grounds, head injuries are leaving lasting marks on the brain in ways we're only ...

Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...

ESA’s Jupiter Icy Moons Explorer (JUICE) that was launched in 2023 will take about 8 years to arrive at the jovian system after several gravity assists. Credit: Space.com | animation courtesy: ESA / ...

In 2019 I wrote about research suggesting anti-inflammatory medications might help some people with major depression. At the time, the idea that depression could have roots in the immune system felt ...

The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Few films end with a line that doubles as a mission statement, distilling both the story’s themes and the creators’ intents. “Arco” fits the bill, captured in its final words: “I wish that things ...

After announcing the Android 16-based OxygenOS 16, OnePlus has begun rolling out this new operating system globally. The OnePlus 12R is the latest device to receive this update. The update is ...

The OnePlus Open is now receiving the Android 16-based OxygenOS 16 update, following the rollout for the OnePlus 12 and 13R. The global model is included, with the update starting in India before ...

Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...

FDA approval enables Complement Therapeutics to start the Opti-GAIN phase 1/2 trial for CTx001 in GA secondary to AMD. CTx001 is an AAV-based gene therapy delivering a truncated Complement Receptor 1 ...